Search Results

BioDuro-Sundia announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas Ph.D. and Zach Sweeney Ph.D. as its members.

BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs.

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a 40,000 ft2 commercial oral solid dose manufacturing facility located at 72 Fairbanks, Irvine, CA, USA.

BioDuro, LLC, announced today the appointment of two senior leadership positions to the Global CMC Solutions business unit: Firouz Asgarzadeh, PhD as Vice President of Pharmaceutics and Mindy Weir as Executive Director Quality. “BioDuro is

BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract rese

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services.

Enteris BioPharma, Inc. announced that John Vrettos, Ph.D., Senior Principal Scientist and Head of Formulation Development at Enteris, has been invited to participate in a webinar series hosted by BIODURO LLC highlighting advances in drug formulation and delivery.

BioDuro, LLC, a leading global life sciences contract research, development and manufacturing services organization, announced today the appointment of Jeffery Blazevich as the new Chief Financial Officer.

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has initiated a COVID-19 nanobody therapeutic program, leveraging the company’s biologics discovery platform and a specialized COVID-19 dedicated team.